期刊
MATERIALS TODAY BIO
卷 16, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.mtbio.2022.100350
关键词
Hepatocellular carcinoma; Tim-3 siRNA; Sorafenib; pH -triggered nanoparticle; Co -delivery
资金
- National Natural Science Foundation of China [81701814]
- Fundamental Research Funds for the Central Universities of Xi'an Jiaotong University [xjj2018270]
- Innovation Capacity Support Plan of Shaanxi Province [2020TD-040]
A pH-triggered drug-eluting nanoparticle was developed for simultaneous delivery of Tim-3 siRNA and sorafenib to hepatocellular carcinoma (HCC), enhancing their anti-tumor efficacy.
Effective systemic treatment for hepatocellular carcinoma (HCC) remains urgently needed. Sorafenib is the first FDA-approved systemic treatment for HCC. However, individual HCC patents??? response to sorafenib varies greatly. How to enhance the anti-HCC effect of sorafenib is still a significant challenge. T cell immunoglobulin mucin-3 (Tim-3) is a newly identified immune checkpoint molecule and a promising target for HCC treatment. Herein, we developed a novel pH-triggered drug-eluting nanoparticle (CC@SR&SF@PP) for simultaneously de-livery of Tim-3 siRNA and sorafenib to HCC in situ. By a single emulsification method, a representative HCC targeted-therapeutic drug sorafenib (SF) was encapsulated into the pH-triggered positive-charged mPEG5K-PAE10K (PP) nanoparticles, followed by condensing of negative-charged Tim-3 siRNA. Then, carboxymethyl chitosan (CMCS), an amphoteric polysaccharide with negative charge in the physiological pH and positive charge in the acidic environment of the tumor, was eventually adsorbed onto the surface of nanoparticles. This co -delivery nanoparticle rapidly and specifically accumulated in the tumor site of the liver and enhanced the tar-geted, specific and multiple release of siRNA and sorafenib. Enhanced Tim-3 siRNA transfected into tumor cells can not only directly inhibit the growth of tumor cells by knock down the expression Tim-3, but also induce the immune response and enhance the recruitment of cytotoxic T cells to kill tumor cells. The following pH-triggered sorafenib release from SF@PP NPs greatly inhibited the tumor proliferation and angiogenesis, resulting in remarkable tumor growth inhibition in a mouse hepatoma 22 (H22) orthotopic tumor model. Thus, co-delivery of Tim-3 siRNA and sorafenib via this novel pH triggered drug-eluting nanoparticle enhances their anti-tumor ef-ficacy. We expect that such combination treatment strategy will have great potential in future clinical applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据